Burden of Antimicrobial Resistance in Adult Hospitalized Patients With Cancer: A Multicenter Analysis
Cancer Medicine · 2024
DOI: 10.1002/cam4.70495 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Vikas Gupta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Becton, Dickinson and Company, Franklin Lakes, NJ, USA. Hauptthemen laut MEDLINE: Neoplasms, Hospitalization, Anti-Bacterial Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMR Action Fund.
Abstract (Originalsprache)
Background
Infections are a leading cause of death in patients with cancer, but the proportion and rate of antimicrobial resistance (AMR) in hospitalized patients with cancer are not well understood.
Methods
This retrospective, cross‐sectional evaluation of AMR assessed hospitalized adult patients in 168 United States (US) healthcare facilities between April 2018 and December 2022. Nonduplicate, noncontaminant Gram‐negative and Gram‐positive bacteria recovered from various samples (blood, respiratory, urine, etc.) were used to assess the rate of AMR pathogens per 1000 admissions and the proportion of AMR among bacterial isolates in patients with and without cancer.
Findings
Among 4,612,620 admissions, 6.4% (297,500) were of patients with cancer and 93.6% (4,315,120) were of patients without cancer. AMR pathogen rates were higher in cancer patients than patients without cancer for most pathogen groups, including vancomycin‐resistant enterococci with incidence rate ratio (IRR), 1.95 (95% confidence interval [CI], 1.84, 2.07), extended‐spectrum beta‐lactamase (ESBL) producers (IRR, 1.48 [95% CI, 1.43, 1.53]), carbapenem‐nonsusceptible Enterobacterales (IRR, 1.46 [95% CI, 1.32, 1.61]), and multidrug‐resistant Pseudomonas aeruginosa (IRR, 1.31 [95% CI, 1.18, 1.45]). The percentage of nonsusceptible isolates in most pathogen groups was lower in patients with versus without cancer except for ESBL producers among Enterobacterales (odds ratio (OR), 1.11 [95% CI, 1.07, 1.15]) and vancomycin resistance among enterococci (OR, 1.22 [95% CI, 1.14, 1.30]), which were higher in cancer patients.
Conclusion
AMR rates for certain key pathogens were 1.5–2 times greater in hospitalized cancer patients compared to hospitalized noncancer patients. The increased AMR rate in cancer patients highlights the need for enhanced infection prevention and diagnostic stewardship efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Becton, Dickinson and Company, Franklin Lakes, NJ, USA.
- Transplant-Oncology Infectious Diseases Program, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
- Department of Medicine (Hematology-Oncology Division), University of Pennsylvania, Philadelphia, PA, USA.
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
- Resonance Inc., Arlington, TN, USA.
ORCID-Profile: Lillian Sung, Diane C Flayhart
Förderung
- AMR Action Fund
Zitieren
APA
Gupta, V., Satlin, M. J., Yu, K., Martei, Y. M., Sung, L., Westblade, L. F., Howard, S. C., Ai, C., & Flayhart, D. C. (2024). Burden of Antimicrobial Resistance in Adult Hospitalized Patients With Cancer: A Multicenter Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.70495
Vancouver
Gupta V, Satlin MJ, Yu K, Martei YM, Sung L, Westblade LF, et al. Burden of Antimicrobial Resistance in Adult Hospitalized Patients With Cancer: A Multicenter Analysis. Cancer Medicine. 2024. doi:10.1002/cam4.70495
BibTeX
@article{Gupta2024,
author = {Gupta, Vikas and Satlin, Michael J and Yu, Kalvin and Martei, Yehoda M and Sung, Lillian and Westblade, Lars F and Howard, Scott C and Ai, ChinEn and Flayhart, Diane C},
title = {Burden of Antimicrobial Resistance in Adult Hospitalized Patients With Cancer: A Multicenter Analysis},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70495}
}
EUVIMED